{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:37:31Z","timestamp":1789097851975,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Hubei Chen Xiaoping Science and Technology Development Foundation Youth Science Special Fund","award":["CXPJJH123001-2320"],"award-info":[{"award-number":["CXPJJH123001-2320"]}]},{"name":"The 2024 Chutian Talents Program Special Fund"},{"name":"Subject of Biomedical Research Center of Hubei Cancer Hospital","award":["2022SWZX09"],"award-info":[{"award-number":["2022SWZX09"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["2042019kf0229"],"award-info":[{"award-number":["2042019kf0229"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81802895"],"award-info":[{"award-number":["81802895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Hubei Province, China","award":["2023AFB493"],"award-info":[{"award-number":["2023AFB493"]}]},{"name":"the National Key Clinical Specialty Construction Project Fund of the Breast Center, Hubei Cancer Hospital","award":["HBCHBCC-A02"],"award-info":[{"award-number":["HBCHBCC-A02"]}]},{"name":"Scientific Research Projects of Hubei Cancer Hospital","award":["2024HBCHYN11"],"award-info":[{"award-number":["2024HBCHYN11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13693-0","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:35:01Z","timestamp":1739882101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment"],"prefix":"10.1186","volume":"25","author":[{"given":"Xinhong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liantao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongcheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"13693_CR1","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"issue":"11","key":"13693_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"13693_CR3","doi-asserted-by":"crossref","unstructured":"Mohanraj B, Duan G, Peredo A, Kim M, Tu F, Lee D, Dodge GR, Mauck RL. Mechanically-Activated Microcapsules for \u2018On-Demand\u2019 Drug Delivery in Dynamically Loaded Musculoskeletal Tissues. Adv Funct Mater 2019, 29(15).","DOI":"10.1002\/adfm.201807909"},{"issue":"24","key":"13693_CR4","doi-asserted-by":"publisher","first-page":"e2200200119","DOI":"10.1073\/pnas.2200200119","volume":"119","author":"G Wang","year":"2022","unstructured":"Wang G, Kumar A, Ding W, Korangath P, Bera T, Wei J, Pai P, Gabrielson K, Pastan I, Sukumar S. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study. Proc Natl Acad Sci U S A. 2022;119(24):e2200200119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"106","key":"13693_CR5","doi-asserted-by":"publisher","first-page":"106ra108","DOI":"10.1126\/scitranslmed.3002368","volume":"3","author":"V Stearns","year":"2011","unstructured":"Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, et al. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med. 2011;3(106):106ra108.","journal-title":"Sci Transl Med"},{"issue":"3","key":"13693_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccell.2016.02.002","volume":"29","author":"G Sflomos","year":"2016","unstructured":"Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, Raffoul W, Delaloye JF, Treboux A, Fiche M, et al. A preclinical model for ERalpha-Positive breast Cancer points to the epithelial microenvironment as determinant of Luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407\u201322.","journal-title":"Cancer Cell"},{"issue":"11","key":"13693_CR7","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445\u201352.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13693_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","volume":"71","author":"MJ Towle","year":"2011","unstructured":"Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71(2):496\u2013505.","journal-title":"Cancer Res"},{"issue":"6","key":"13693_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110(6):1497\u2013505.","journal-title":"Br J Cancer"},{"issue":"10","key":"13693_CR10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334\u201342.","journal-title":"Cancer Sci"},{"issue":"38","key":"13693_CR11","doi-asserted-by":"publisher","first-page":"e2203019","DOI":"10.1002\/adma.202203019","volume":"34","author":"P Wu","year":"2022","unstructured":"Wu P, Zhang H, Sun M, Mao S, He Q, Shi Y, Deng Y, Dong Z, Xu Q, Zhao C, et al. Manipulating offense and Defense Signaling to Fight Cold tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA. Adv Mater. 2022;34(38):e2203019.","journal-title":"Adv Mater"},{"issue":"15","key":"13693_CR12","doi-asserted-by":"publisher","first-page":"e2309591","DOI":"10.1002\/adma.202309591","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Chen Y, Wei R, Zhang J, Zhu J, Wang W, Wang Z, Wupur Z, Li Y, Meng H. Synergistic chemoimmunotherapy augmentation via sequential nanocomposite hydrogel-mediated reprogramming of Cancer-Associated fibroblasts in Osteosarcoma. Adv Mater. 2024;36(15):e2309591.","journal-title":"Adv Mater"},{"issue":"1","key":"13693_CR13","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/s41467-021-22235-8","volume":"12","author":"Z Zou","year":"2021","unstructured":"Zou Z, Hu X, Luo T, Ming Z, Chen X, Xia L, Luo W, Li J, Xu N, Chen L, et al. Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor. Nat Commun. 2021;12(1):2263.","journal-title":"Nat Commun"},{"issue":"1","key":"13693_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12967-023-04055-0","volume":"21","author":"H Zhao","year":"2023","unstructured":"Zhao H, Jiang R, Zhang C, Feng Z, Wang X. LncRNA H19-rich extracellular vesicles derived from gastric cancer stem cells facilitate tumorigenicity and metastasis via mediating intratumor communication network. J Transl Med. 2023;21(1):238.","journal-title":"J Transl Med"},{"issue":"2","key":"13693_CR15","doi-asserted-by":"publisher","first-page":"112157","DOI":"10.1016\/j.yexcr.2020.112157","volume":"394","author":"JH Liu","year":"2020","unstructured":"Liu JH, Chen C, Li ZY, Zou ZM, Gao DC, Zhang X, Kuang XW, Sun ZH, Zheng WJ, Zhou P, et al. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88\/GSK-3beta and MyD88\/NF-kappaB signalling pathways. Exp Cell Res. 2020;394(2):112157.","journal-title":"Exp Cell Res"},{"issue":"5","key":"13693_CR16","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/cas.15300","volume":"113","author":"BQ Shan","year":"2022","unstructured":"Shan BQ, Wang XM, Zheng L, Han Y, Gao J, Lv MD, Zhang Y, Liu YX, Zhang H, Chen HS, et al. DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting PERP expression. Cancer Sci. 2022;113(5):1587\u2013600.","journal-title":"Cancer Sci"},{"issue":"8","key":"13693_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994\u20131004.","journal-title":"Ann Oncol"},{"issue":"9737","key":"13693_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235\u201344.","journal-title":"Lancet"},{"key":"13693_CR19","doi-asserted-by":"crossref","unstructured":"Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C et al. Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer 2020, 8(2).","DOI":"10.1136\/jitc-2020-000664"},{"issue":"12","key":"13693_CR20","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S. Antibody-drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B. 2021;11(12):3889\u2013907.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"13693_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","volume":"31","author":"C Corti","year":"2022","unstructured":"Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investig Drugs. 2022;31(6):593\u2013605.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"13693_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16(1):100.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"13693_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"7","key":"13693_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","volume":"30","author":"J Pascual","year":"2019","unstructured":"Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30(7):1051\u201360.","journal-title":"Ann Oncol"},{"issue":"1","key":"13693_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-024-01944-w","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Yu Z, Yang S, Liu Y, Song J, Mao J, Li M, Zhao Y. ZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK\/PI3K\/AKT activation in a ceRNA manner. Mol Cancer. 2024;23(1):33.","journal-title":"Mol Cancer"},{"issue":"16","key":"13693_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, et al. Sacituzumab Govitecan in Metastatic Triple-negative breast Cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"10265","key":"13693_CR27","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"21","key":"13693_CR28","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S, Denkert C, Park YH, Hui R, Harbeck N, et al. Overall survival with Pembrolizumab in Early-Stage Triple-negative breast Cancer. N Engl J Med. 2024;391(21):1981\u201391.","journal-title":"N Engl J Med"},{"key":"13693_CR29","doi-asserted-by":"crossref","unstructured":"Ji T, Kohane DS. Nanoscale systems for local drug delivery. Nano Today 2019, 28.","DOI":"10.1016\/j.nantod.2019.100765"},{"issue":"1","key":"13693_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4049\/jimmunol.1601145","volume":"198","author":"MA Aznar","year":"2017","unstructured":"Aznar MA, Tinari N, Rullan AJ, Sanchez-Paulete AR, Rodriguez-Ruiz ME, Melero I. Intratumoral Delivery of Immunotherapy-Act locally, think globally. J Immunol. 2017;198(1):31\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"13693_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783\u2013801.","journal-title":"Cell"},{"issue":"2","key":"13693_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10911-020-09453-4","volume":"25","author":"XW Kuang","year":"2020","unstructured":"Kuang XW, Liu JH, Sun ZH, Sukumar S, Sun SR, Chen C. Intraductal therapy in breast Cancer: current status and future prospective. J Mammary Gland Biol Neoplasia. 2020;25(2):133\u201343.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"11","key":"13693_CR33","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1093\/carcin\/bgs248","volume":"33","author":"YS Chun","year":"2012","unstructured":"Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, de Wilde RF, Zhang Z, Huso DL, Zhao M, et al. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis. 2012;33(11):2242\u20139.","journal-title":"Carcinogenesis"},{"issue":"217","key":"13693_CR34","doi-asserted-by":"publisher","first-page":"217ra212","DOI":"10.1126\/scitranslmed.3007048","volume":"6","author":"A Brock","year":"2014","unstructured":"Brock A, Krause S, Li H, Kowalski M, Goldberg MS, Collins JJ, Ingber DE. Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice. Sci Transl Med. 2014;6(217):217ra212.","journal-title":"Sci Transl Med"},{"issue":"2","key":"13693_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/0008-5472.CAN-05-4329","volume":"66","author":"S Murata","year":"2006","unstructured":"Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, et al. Ductal access for prevention and therapy of mammary tumors. Cancer Res. 2006;66(2):638\u201345.","journal-title":"Cancer Res"},{"issue":"1","key":"13693_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tips.2022.10.003","volume":"44","author":"L Wu","year":"2023","unstructured":"Wu L, Wang L, Du Y, Zhang Y, Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharmacol Sci. 2023;44(1):34\u201349.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"13693_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrd3144","volume":"9","author":"WN Hait","year":"2010","unstructured":"Hait WN. Anticancer drug development: the grand challenges. Nat Rev Drug Discov. 2010;9(4):253\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"13693_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrd3375","volume":"10","author":"J Arrowsmith","year":"2011","unstructured":"Arrowsmith J. Trial watch: phase III and submission failures: 2007\u20132010. Nat Rev Drug Discov. 2011;10(2):87.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"13693_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.21037\/atm-21-1540","volume":"9","author":"D Gao","year":"2021","unstructured":"Gao D, Liu J, Yuan J, Wu J, Kuang X, Kong D, Zheng W, Wang G, Sukumar S, Tu Y, et al. Intraductal administration of N-methyl-N-nitrosourea as a novel rodent mammary tumor model. Ann Transl Med. 2021;9(7):576.","journal-title":"Ann Transl Med"},{"issue":"36","key":"13693_CR40","doi-asserted-by":"publisher","first-page":"e2205106","DOI":"10.1002\/advs.202205106","volume":"9","author":"D Guo","year":"2022","unstructured":"Guo D, Lei JH, Rong D, Zhang T, Zhang B, Tang Z, Shen HM, Deng CX, Qu S. Photocatalytic pt(IV)-Coordinated Carbon dots for Precision Tumor Therapy. Adv Sci (Weinh). 2022;9(36):e2205106.","journal-title":"Adv Sci (Weinh)"},{"key":"13693_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jconrel.2022.06.039","volume":"348","author":"M Kim","year":"2022","unstructured":"Kim M, Lee JS, Kim W, Lee JH, Jun BH, Kim KS, Kim DE. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022;348:893\u2013910.","journal-title":"J Control Release"},{"issue":"12","key":"13693_CR42","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/nm.1791","volume":"14","author":"P Eirew","year":"2008","unstructured":"Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT, Eaves CJ. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med. 2008;14(12):1384\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"13693_CR43","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61(3):1013\u201321.","journal-title":"Cancer Res"},{"issue":"5381","key":"13693_CR44","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1126\/science.281.5381.1312","volume":"281","author":"NA Thornberry","year":"1998","unstructured":"Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281(5381):1312\u20136.","journal-title":"Science"},{"issue":"16","key":"13693_CR45","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64(16):5760\u20136.","journal-title":"Cancer Res"},{"issue":"6","key":"13693_CR46","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594\u2013601.","journal-title":"J Clin Oncol"},{"key":"13693_CR47","doi-asserted-by":"crossref","unstructured":"Masuda T, Ueo H, Kai Y, Noda M, Hu Q, Sato K, Fujii A, Hayashi N, Tsuruda Y, Otsu H et al. N-Cadherin mRNA levels in Peripheral Blood could be a potential Indicator of New metastases in breast Cancer: a pilot study. Int J Mol Sci 2020, 21(2).","DOI":"10.3390\/ijms21020511"},{"issue":"7","key":"13693_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"13693_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"13693_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487\u2013500.","journal-title":"Nat Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13693-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:37:23Z","timestamp":1739882243000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13693-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13693"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13693-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"5 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The People\u2019s Hospital of Wuhan University\u2019s Animal Ethics Committee approved this round of animal testing (IACUC Issue No. 20200702), and all ethical guidelines were strictly followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}